LivingGLP1
Study S002367

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

ClinicalTrials.gov record

Registration

Registration
NCT05419726
Study type
OBSERVATIONAL
Status
RECRUITING
Enrollment
20
Start
2023-02-01
Primary completion
2026-01-01
Lead sponsor
University of California, Los Angeles
Conditions
Obesity
Interventions
DRUG:Semaglutide Injectable Product (not provided by the study)
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • change in supraclavicular temperature with cold exposure [20weeks]
  • change in caloric intake [20weeks]
  • basal metabolic rate [20 weeks]

Linked records (11)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0017879Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue.
Oliveira FCB, Frontiers in endocrinology
2021Randomized trialPMID 35069450DOIregistry reference BACKGROUND:35069450
R0020733The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
Stafeev I, Current molecular medicine
2021Narrative reviewPMID 33261539DOIregistry reference BACKGROUND:33261539
R0020707Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.
van Eyk HJ, Nutrition, metabolism, and cardiovascular diseases : NMCD
2020Randomized trialPMID 32127340DOIregistry reference BACKGROUND:32127340
R0021522Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.
Janssen LGM, Metabolism: clinical and experimental
2020Nonrandomized studyPMID 31982480DOIregistry reference BACKGROUND:31982480
R0020434Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats.
Krieger JP, American journal of physiology. Regulatory, integrative and comparative physiology
2018PreclinicalPMID 29847161DOIregistry reference BACKGROUND:29847161
R0020555Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity.
Lee SJ, Molecular metabolism
2018PreclinicalPMID 29650350DOIregistry reference BACKGROUND:29650350
R0016392GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Beiroa D, Diabetes
2014PreclinicalPMID 24917578DOIregistry reference BACKGROUND:24917578
R0024303Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M, Diabetes research and clinical practice
2012Randomized trialPMID 22446097DOIregistry reference BACKGROUND:22446097
R0026590Alterations in energy balance following exenatide administration.
Bradley DP, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme
2012Other trialPMID 22735035DOIregistry reference BACKGROUND:22735035
R0056843Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling.
Lockie SH, Diabetes
2012PreclinicalPMID 22933116DOIregistry reference BACKGROUND:22933116
R0026652The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
Harder H, Diabetes care
2004Randomized trialPMID 15277417DOIregistry reference BACKGROUND:15277417